Critical Comparison: RXi Pharmaceuticals Corporation (RXII) & Its Peers
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is one of 189 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare RXi Pharmaceuticals Corporation to similar businesses based on the strength of its risk, dividends, valuation, earnings, analyst recommendations, profitability and institutional ownership.
Volatility & Risk
RXi Pharmaceuticals Corporation has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, RXi Pharmaceuticals Corporation’s peers have a beta of 1.49, suggesting that their average share price is 49% more volatile than the S&P 500.
This is a breakdown of current ratings and price targets for RXi Pharmaceuticals Corporation and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|RXi Pharmaceuticals Corporation||0||0||0||0||N/A|
|RXi Pharmaceuticals Corporation Competitors||465||2185||6135||118||2.66|
RXi Pharmaceuticals Corporation presently has a consensus price target of $1.71, indicating a potential upside of 219.69%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 24.01%. Given RXi Pharmaceuticals Corporation’s higher possible upside, equities analysts plainly believe RXi Pharmaceuticals Corporation is more favorable than its peers.
This table compares RXi Pharmaceuticals Corporation and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|RXi Pharmaceuticals Corporation||N/A||-136.73%||-91.04%|
|RXi Pharmaceuticals Corporation Competitors||-4,931.88%||-128.76%||-45.78%|
Institutional and Insider Ownership
1.7% of RXi Pharmaceuticals Corporation shares are held by institutional investors. Comparatively, 47.2% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 5.7% of RXi Pharmaceuticals Corporation shares are held by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares RXi Pharmaceuticals Corporation and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|RXi Pharmaceuticals Corporation||$20,000.00||-$8.99 million||-0.41|
|RXi Pharmaceuticals Corporation Competitors||$216.12 million||-$47.68 million||-98.00|
RXi Pharmaceuticals Corporation’s peers have higher revenue, but lower earnings than RXi Pharmaceuticals Corporation. RXi Pharmaceuticals Corporation is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
RXi Pharmaceuticals Corporation peers beat RXi Pharmaceuticals Corporation on 5 of the 9 factors compared.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.
Receive News & Stock Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related stocks with our FREE daily email newsletter.